Navigation Links
Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitor's
Date:9/14/2007

Roche test processes 50 percent more samples in 1-day shift

INDIANAPOLIS, Sept. 14 /PRNewswire/ -- Roche Diagnostics' newly developed, automated real-time PCR test for HIV provides shorter turnaround time and less hands-on labor than one of its main competitors, according to a new study published in Clinical Chemistry and Laboratory Medicine in July.

The study, conducted by Medical Laboratory Bremen, concludes that Roche's new HIV-1 test used with the COBAS(R) Ampliprep/COBAS(R) TaqMan(R) (CAP/CTM) can save laboratories 30 minutes of workflow time and can process up to 50 percent more samples in a one-day shift, compared with Abbott's RealTime HIV test using m2000sp and m2000rt.

The research compared 102 plasma samples from HCV patients, 109 samples from HIV patients and 10 samples from negative donors. Roche has filed with the U.S. Food & Drug Administration for approval to use the HCV test on the CAP/CTM in the United States. The widely used, semi-automated COBAS Amplicor Monitor assay served as the reference test.

"The results indicate that real-time PCR assays can improve on the efficiency of end-point PCR tests by better covering viral dynamic ranges and providing high throughput and automation," said Dr. Dietmar Wolff, author of "Comparison of the Roche COBAS Amplicor Monitor, Roche COBAS Ampliprep/COBAS Taqman and Abbott RealTime Test assays for quantification of hepatitis C virus and HIV RNA."

In addition, the study highlighted some key performance differences between the COBAS Ampliprep/COBAS Taqman and Abbott RealTime assays using m2000sp and m2000rt.

Workflow is so critical to laboratories that Wolff wanted to develop a practical measurement by running the systems at full capacity in a one-day shift simulation.

"CAP/CTM could process 72 samples in a one-day shift, while RealTime could only process 48 samples," Wolff said. "This difference is due to the significant reduction in manual intervention required by CAP/CTM, an integrated system in which samples are processed for extraction and real-time PCR by two dedicated instruments physically linked by a robotic arm."

About Roche and the Roche Diagnostics Division

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our U.S. Web site at http://www.roche-diagnostics.us.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Lori McLaughlin

Corporate Communications

Roche Diagnostics Corporation

Indianapolis, Ind.

Phone: 317-521-3112

lori.mclaughlin@roche.com


'/>"/>
SOURCE Roche Diagnostics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Advantages of Roche Applied Science amplification products
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. NimbleGen to discontinue IPO after Roches $272.5 million acquisition
5. Prodesse enters patent agreement with Roche
6. Critical factors for successful microarray and real-time PCR analyses
7. Measuring RNase Activity A Real-time Kinetic Analysis
8. Ready for Real-time in 5 Minutes
9. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
10. YOUR DATA: Direct Real-time RT-PCR on Sympathetic Neuron Lysates Silencing of Focal Adhesion Kinases with Silencer Validated siRNAs
11. Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... February 27, 2017 A Europe-wide survey of ... researchers using animals in their research treat them with due care. ... and detailed analysis of the results indicates that there is a ... to put into practice the principles of the 3Rs (Refine, ... What ...
(Date:2/27/2017)... Feb. 27, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the U.S. Food and Drug Administration (FDA) has ... section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual ... with moderate-to-severe acute pain in a medically supervised ...
(Date:2/27/2017)... and HAMILTON, Bermuda ... (NASDAQ: ADXS ) and ... companies focused on developing cancer immunotherapies, today announced ... develop a novel cancer immunotherapy agent using Advaxis, ... SELLAS, patented WT1 targeted heteroclitic peptide antigen mixture ...
(Date:2/27/2017)... ... February 27, 2017 , ... In starting a program to hire ... grandfather, “Hire for attitude. Train for skill.” , In keeping with this philosophy, the ... as a salesman. Zamzow is hoping to replicate the practice throughout the company. , ...
Breaking Biology Technology:
(Date:2/8/2017)... AWRE ), a leading supplier of biometrics software ... year ended December 31, 2016. Revenue for ... $6.9 million in the same quarter last year. Operating income ... to $2.6 million in the fourth quarter of 2015. Net ... or $0.02 per diluted share, which compares to $1.8 million, ...
(Date:2/8/2017)... Report Highlights The global biosurgery market should ... 2016 at a compound annual growth rate (CAGR) of ... An overview of the global market for biosurgery. - ... and 2016, and projections of compound annual growth rates ... the basis of product type, source, application, and region. ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):